KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib...

Area of Science:

• Immunogenetics
• Hematology
• Oncology

Background:

• Killer immunoglobulin-like receptors (KIRs) on natural killer (NK) cells are implicated in predicting treatment response in chronic phase-chronic myeloid leukemia (CP-CML).
• Tyrosine kinase inhibitors (TKIs) are standard therapy for CP-CML.

Purpose of the Study:

• To investigate the prognostic value of KIR genotyping in newly diagnosed CP-CML patients treated with a sequential imatinib/nilotinib strategy.
• To determine if KIR genotypes influence molecular response achievement and survival outcomes.

Main Methods:

• KIR genotyping was performed on 148 newly diagnosed CP-CML patients.
• Patients received a sequential imatinib followed by nilotinib treatment strategy.
• Outcomes assessed included transformation-free survival, event-free survival, major molecular response, and molecular response 4.5.

Main Results:

• The presence of KIR2DL5B was associated with inferior transformation-free survival and event-free survival.
• KIR2DL5B independently predicted for inferior major molecular response and molecular response 4.5.
• These findings suggest NK cell activity early in treatment is crucial and may not be compensated by intensified therapy.

Conclusions:

• KIR genotyping, particularly KIR2DL5B status, provides valuable prognostic information in CP-CML.
• KIR genotyping may aid in optimizing frontline treatment selection for CP-CML patients.
• NK cell involvement early in TKI therapy is critical for treatment success.